Hudson Bay Capital Management LP has made a significant investment in Icon Plc, acquiring 193,000 shares of the medical research company during the second quarter of 2023. The investment is valued at approximately $28.07 million, highlighting the growing interest in the company’s stock.
The investment is part of a broader trend, as several hedge funds have recently adjusted their positions in Icon Plc (NASDAQ: ICLR). Notably, Artisan Partners Limited Partnership increased its stake by an impressive 67.4%, now owning 7,184,870 shares valued at around $1.05 billion after acquiring an additional 2,893,946 shares. Other firms, including Financiere des Professionnels Fonds d’investissement and American Century Companies Inc., have also expanded their holdings, further illustrating institutional confidence in the company.
Institutional investors currently hold approximately 95.61% of Icon Plc‘s stock, underscoring the company’s appeal among professional investment firms.
Analyst Ratings and Stock Performance
Recent analyst reports reflect a mixed outlook for Icon Plc‘s stock. Jefferies Financial Group downgraded the stock from a “buy” rating to a “hold” rating, reducing its price target from $220.00 to $175.00 as of September 9, 2023. Meanwhile, Cowen reiterated a “hold” rating on October 24, 2023, while BMO Capital Markets commenced coverage with a similar “market perform” rating and a target price of $175.00.
The consensus rating for Icon Plc indicates a “Moderate Buy,” with two analysts recommending a strong buy, eight suggesting a buy, and ten advising a hold. The average target price among analysts stands at $205.00.
As of the latest trading session, Icon Plc‘s stock opened at $186.58. The company has demonstrated solid performance metrics, with a market capitalization of approximately $15.07 billion, a price-to-earnings ratio of 25.25, and a beta of 1.25. Over the past year, the stock has fluctuated between a low of $125.10 and a high of $228.29.
About Icon Plc
Icon Plc is a prominent clinical research organization that provides outsourced development and commercialization services across various regions, including Ireland, Europe, and the United States. The company focuses on strategic development and management of clinical programs, supporting projects from initial compound selection through to Phase I-IV clinical studies.
With its robust portfolio and institutional backing, Icon Plc remains a key player in the medical research sector, poised for continued growth amid evolving market conditions.
